# Empagliflozin in Hypertrophic Cardiomyopathy

Study · id `cardio:ct-nct05182658` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05182658](<https://clinicaltrials.gov/study/NCT05182658>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05182658

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 250 participants.

## Technical summary

Registry record NCT05182658. Randomized; triple masking; primary purpose treatment. Start 2022-06-01 (actual); primary completion 2026-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT05182658, source copy `cardio:ctgov-nct05182658-2026-03-12`, retrieved 2026-10-26)
- Started: 2022-06-01 (actual) (ClinicalTrials.gov record NCT05182658, source copy `cardio:ctgov-nct05182658-2026-03-12`, retrieved 2026-10-26)
- Primary completion: 2026-09-30 (anticipated) (ClinicalTrials.gov record NCT05182658, source copy `cardio:ctgov-nct05182658-2026-03-12`, retrieved 2026-10-26)
- Completion: 2026-11-30 (anticipated) (ClinicalTrials.gov record NCT05182658, source copy `cardio:ctgov-nct05182658-2026-03-12`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT05182658, source copy `cardio:ctgov-nct05182658-2026-03-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05182658-2026-03-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Empagliflozin in Hypertrophic Cardiomyopathy
- Acronym: EMPA-REPAIR
- Condition: Hypertrophic Cardiomyopathy
- Condition: Heart Failure
- Intervention (Drug): Empagliflozin 10 MG
- Intervention (Drug): Placebo
- Lead sponsor: National Institute of Cardiology, Warsaw, Poland
- Lead sponsor class: OTHER
- Collaborator: Medical University of Bialystok
- Collaborator class: OTHER
- Collaborator: University of Eastern Finland
- Collaborator class: OTHER
- Collaborator: Amsterdam UMC, location VUmc
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: National Institute of Cardiology, Warsaw, Poland (`cardio:org-national-institute-of-cardiology-warsaw-poland`)
- Registry lists this organization as a collaborator: Amsterdam UMC, location VUmc (`cardio:org-amsterdam-umc-location-vumc`)

## Provenance

Content hash: e707e1705d96e986a7dcb6fe5512926315cbc8c3c712bd638978cbe8aeb9c440
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
